trending Market Intelligence /marketintelligence/en/news-insights/trending/_DXZzjbpa4jMaALLEqKNfw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

US judge may reject Novelion unit's deal with DOJ

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US judge may reject Novelion unit's deal with DOJ

U.S. District Judge William Young may reject the plea agreement between Aegerion Pharmaceuticals Inc. and the U.S. Department of Justice, Reuters reported.

In September, the Novelion Therapeutics Inc. unit agreed to plead guilty to charges relating to its high-cholesterol drug Juxtapid and pay $36 million to resolve criminal and civil liability arising from the charges.

Young did not issue a definitive rejection of the plea agreement at a court hearing in Boston but noted that his instinct was to reject the deal, the news outlet reported.